femasys(FEMY) - 2025 Q4 - Annual Results

Financial Results for Year Ended December 31, 2025 Exhibit 99.1 Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update -- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- ATLANTA, March 31, 2026 – Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results ...